| Autor: |
XU Wenwen, ZHU Yuxi |
| Jazyk: |
čínština |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Zhongliu Fangzhi Yanjiu, Vol 48, Iss 12, Pp 1129-1134 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1000-8578 |
| DOI: |
10.3971/j.issn.1000-8578.2021.21.0761 |
| Popis: |
The individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantly increased the effective rate, progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation, especially the brain metastases. And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated non-small cell lung cancer. Moreover, the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated non-small cell lung cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
